BD and U.S. Government Partner to Expand Domestic Manufacturing of Essential Medical Consumables

AméricasNotícias de última horaCuidado & TerapiaDesenvolvimento estratégico

BD (Becton, Dickinson and Company) has announced a landmark partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for essential medical consumables relied on by clinicians and patients every day. The agreement supports significant investments in U.S. manufacturing, innovation, and end-to-end production capabilities, and aligns with the Trump administration’s efforts to expand domestic manufacturing capacity and ensure a resilient supply chain for products critical to patient care and healthcare preparedness.

Through the partnership, BD intends to invest $19 billion in the U.S. over several years, including capital, operational, and supply chain investments, with $3 billion of the overall investment directed toward U.S. manufacturing expansion focused on strategic production sites across the country. The company plans to expand end-to-end U.S. production by approximately 5 billion essential medical consumables annually, raising BD’s share of domestically supplied essential medical consumables to roughly 80%, and to manufacture 100% of BD needles used in America domestically using American-made steel.

The agreement also provides relief from future tariffs imposed under Section 232 on covered BD products and inputs, subject to the final scope and implementation of any future Section 232 actions and BD’s achievement of agreed milestones. This provides greater long-term certainty for manufacturing and supply chain planning as BD advances investments in U.S. production, innovation, and healthcare infrastructure. Because the final tariff rates, product scope, and effective timing have not yet been determined, BD is not currently quantifying the financial impact of the agreement and expects to provide additional information when the Section 232 tariffs are finalized.

BD’s U.S. manufacturing network includes sites in Columbus and Broken Bow, Nebraska; Canaan, Connecticut; Añasco, Puerto Rico; Sandy, Utah; El Paso, Texas; Covington, Georgia; and Sumter, South Carolina. For nearly 130 years, BD has partnered with health systems and governments to meet critical healthcare challenges, from developing the first disposable syringe that helped advance the fight against polio to delivering more than two billion additional devices during the recent pandemic. Collectively, these commitments are intended to help establish one of the world’s most resilient essential medical consumables manufacturing bases and strengthen America’s healthcare resilience for future generations.

Tom Polen, Chairman, CEO, and President of BD, said the agreement reflects a shared commitment between the U.S. Government and BD to strengthening America’s healthcare infrastructure, expanding U.S. manufacturing capacity, and supporting reliable access to essential medical technologies. Polen noted that the administration recognizes the importance of investing in a stronger, more secure healthcare supply chain, and that BD is uniquely positioned to help bring that vision to life through its scale, innovation expertise, and longstanding U.S. manufacturing footprint. Polen added that BD is proud to build on its legacy through significant investment in U.S. manufacturing and innovation while continuing to serve patients, providers, and communities around the world who depend on the company.